• AMD
• BA
• CL
• FSLR
• GOOGL
• HK50
• MCD
• PFE
• UK100
• US10YT=X
• US2YT=X
• US5YT=X
• USD/CNY

Morning Bid: Election-agitated Treasuries meet megacap earnings

U.S. markets show mixed signals amid election anxiety, rising Treasury yields, and fluctuating global economic indicators as companies prepare for corporate earnings reports.

• DHI
• ESZ24
• F
• GOGL34
• MCD
• MSFT
• NQZ24
• NVDA
• PFE
• TSLA
• US10YT=X
• VFC
• VIX

Wall Street muted ahead of Alphabet earnings

Wall Street remained stable as investors analyzed corporate earnings and awaited Alphabet's report, amidst rising bond yields and mixed earnings from tech companies.

• PFE

Pfizer management looks to show turnaround as Starboard looms

• AMGN
• AZN
• CTLT
• NVO
• PFE
• RHHBY

Roche comes out against allowing takeover of drug manufacturer Catalent

Roche's CEO urged authorities to block Novo Nordisk's acquisition of Catalent, citing potential competition issues in the weight-loss drug market, raising concerns for smaller competitors.

• PFE

Starboard Value CEO says Pfizer's board should hold management accountable

Starboard Value CEO Jeffrey Smith urges Pfizer's board to hold management accountable for underperformance, highlighting poor drug development and capital allocation impacting the company's market position.

• ADSK
• CRM
• JNJ
• MTCH
• PFE

Starboard Value takes stake in JNJ spin-off Kenvue- WSJ

Starboard Value has acquired a stake in Kenvue Inc, advocating for changes to improve stock performance, while also investing in other major companies like Pfizer.

• BNTX
• PFE

BioNTech shares slip as FDA places partial clinical hold on lung cancer study

BioNTech's shares declined after the FDA imposed a partial clinical hold on a lung cancer trial due to data variances, while existing patients' treatments will proceed as planned.

• PFE

Pfizer fight with Starboard heats up, hedge fund alleges executive pressure

Starboard Value pressures Pfizer to investigate coercive conduct after former executives withdraw support. The clash highlights investor concerns over Pfizer's declining stock and strategic decisions.

• PFE

Former Pfizer CEO, CFO step back from Starboard activist bid

Former Pfizer executives Ian Read and Frank D’Amelio withdraw support from Starboard Value's campaign, backing current CEO Albert Bourla amid shifts in shareholder strategy.

• PFE

Former Pfizer CEO, CFO say they will not be involved in Starboard's campaign against drugmaker

Former Pfizer executives Ian Read and Frank D'Amelio decline to engage with activist investor Starboard Value, emphasizing support for current management amid significant share value decline and revenue challenges.